ClinicalTrials.gg
CompletedNCT06516094Updated Apr 4, 2025

Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic Pain

A Phase 3 interventional study of Celecoxib+Pregabalin+Vitamin B fixed dose and Celecoxib + Vitamin B fixed dose in Chronic Low-back Pain, sponsored by Laboratorios Silanes S.A. de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Laboratorios Silanes S.A. de C.V. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Low Back Pain with a site in Mexico — 2 open to participants now, 2 under way, none of them phase 3. Low Back Pain · Mexico.

Started
2024
the only one that year
Phase 3
3 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
2 of 11
Laboratorios Silanes S.A. de C.V.

Among the 11 studies in Low Back Pain with a site in Mexico, this one is the only one that started in 2024, is one of 3 in phase 3, and was the 9th registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

2 of the 11 studies in Low Back Pain with a site in Mexico are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Low Back Pain with a site in Mexico, or all of them as a file.
02

Study summary

Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and security of the drug combination of Celecoxib / Pregabalin / Vitamin B versus Celecoxib + Vitamin B, versus Pregabalin + Vitamin B in the treatment of chronic low back pain.

Read the detailed description

Researchers will compare the fixed-dose combination of Celecoxib/Pregabalin/Vitamin B versus Celecoxib + Vitamin B versus Pregabalin + Vitamin B for chronic low back pain. The adverse events related to the interventions would be registered in each follow up visit.

Participants will:

  • Be randomized into one of the 3 intervention groups (A,B,C) once a day for 12 weeks
  • If needed the dose could be escaleted twice a day.
  • Visit the clinic at weeks 2, 4, 8 and 12 for checkups and follow up
03

Conditions studied

  • Chronic Low-back Pain

Keywords

  • Low-back pain
  • Chronic pain
  • Vitamin B
  • Pregabalin
  • Celecoxib
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Agree to participate in the study and give written
  • Subjects must have chronic low back pain with a high probability of a significant neuropathic component during 4 years or less (but not less than 3 months)
  • Patients with chronic low back pain reported as moderate to severe intensity (EVA ≥ 40 mm)
  • Patients with Neuropathic Pain Questionnaire (DN4) result ≥ 4
  • Women of under a medically acceptable method of

Exclusion criteria

Exclusion Criteria:

  • Patients participating in another clinical trial involving an treatment or participation in one within 4 weeks prior to study start
  • Patients whose participation in the study may be influenced (employment relationship with the research site or sponsor, inmates, etc.)
  • At medical discretion, a disease that affects prognosis and prevents outpatient management, for example, but not limited to: end-stage cancer, kidney, heart, respiratory or liver failure, mental illness or with scheduled surgical or hospital procedures
  • History/presence of any disease or condition that, in the opinion of the Investigator, could pose a risk for the patient or confusing the efficacy and safety of the investigational product
  • Patients in whom the study drug is for medical reasons
  • Patients with allergy or to the active substance of the study drugs, related products or
  • Pregnant women, women breastfeeding or planning a pregnancy during the conducting the study
  • Significant history of gastrointestinal diseases (e.g., gastric ulcer, Crohn's disease, Ulcerative Colitis, etc.)
  • Current treatment with opioids and/or NSAIDs including COX-2 inhibitors (except celecoxib), reported in clinical history in the last 24 hours to the signing of the
  • Patients who are receiving monoamineoxidase inhibitors (MAOIs) or who have received them in the course of the 2 weeks prior to signing the informed consent
  • Patients with a history of alcohol or drug abuse in the last year
  • Patients with a history of ischemic heart disease, peripheral artery disease, and/or cerebral vascular disease (including patients who have recently undergone coronary revascularization or angioplasty)
  • Patients with a history of seizures, epileptic status and/or grand mal seizures
  • History of chronic liver failure A, B, and/or C
  • History of acute renal failure ( \<30 ml/min/1.72 m2)
  • Patient with a history of chronic pain associated with fibromyalgia, Paget's disease or bone pain induced by cancer
  • History of major trauma to the lower back in the past 14 days
  • Low back pain due to a visceral disorder (e.g., dysmenorrhea, history of endometriosis)
  • Patients with a history of orthopedic surgery of the lumbar region secondary to chronic low back pain
  • Patients with symptoms suggestive of COVID-19 infection (fever, cough, dyspnea) and/or contact in the last 14 days with a suspected or positive patient for COVID-19
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Celecoxib+Pregabalin+Vitamin B(thiamine mononitrate/pyridoxone hydrochloride/cyanocobalamin)+Placebo

    Administered orally, 1 tablet + 1 capsule a day, for 3 months.

    Drug: Celecoxib+Pregabalin+Vitamin B fixed dose

  • Active comparator
    Celecoxib + Vitamin B (thiamine mononitrate/ pyridoxone hydrochloride/ cyanocobalamin)

    Administered orally, 1 capsule + 1 tablet a day, for 3 months

    Drug: Celecoxib + Vitamin B fixed dose

  • Active comparator
    Pregabalin + Vitamin B (thiamine mononitrate/ pyridoxone hydrochloride/ cyanocobalamin)

    Administered orally, 1 capsule + 1 tablet a day, for 3 months

    Drug: Pregabalin + Vitamin B fixed dose

Interventions

  • DrugCelecoxib+Pregabalin+Vitamin B fixed dose

    One tablet of 200 mg / 150 mg / 100 mg / 50 mg / 0.50 mg + 1 capsule of placebo once a day

    Also known as: Cele+Pre+Vit B

  • DrugCelecoxib + Vitamin B fixed dose

    One capsule of 200 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day

    Also known as: Cele+Vit B

  • DrugPregabalin + Vitamin B fixed dose

    One capsule of 150 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day

    Also known as: Pre+Vit B

06

What researchers measure

Primary outcomes

  1. Comparison of the percentage change of Celecoxib / Pregabalin / Vitamin B Combination versus Celecoxib + Vitamin B versus Pregabalin + Vitamin B in the management of chronic low back pain through the visual analog pain scale (VAS).

    The visual analog pain scale (VAS) is a straight line in which one end signifies absence of pain and the other means the worst pain imaginable. The researcher will apply the VAS scale to each patient at each visit to assess pain intensity. At the end of the clinical trial the change porcentage will be measured and compared between treatment groups.

    Time frame: 3 months

  2. Number of participants with treatment-related adverse events through the patient's diary record.

    To describe the frequency, intensity and causality of the adverse events presented during the clinical trial by treatment group. The adverse events will be registered by the patient in the diary record. Each adverse event will be followed up at the discretion of the researcher.

    Time frame: 3 months

Secondary outcomes

  1. To describe the sociodemographic characteristics of the patients included in the study by treatment group

    A general description of sex, age, race, weight, height and BMI. * Body weight: should be obtained on a scale, with the patient without shoes, in a standing position it would be recorded in kilograms. * Height: must be obtained with a stadimeter, with the patient without shoes, in a standing position, the record will be in meters Height will be measured only at visit 0, and will be taken as a reference for measurement of BMI. * BMI: calculated with the formula: Weight/height2 and will be recorded in kg/m2. Weight and height will be combined to report BMI in kg/m\^2

    Time frame: 3 months

  2. Assess the proportion of patients who reported >30% improvement in pain intensity measured through VAS at 12 weeks per treatment group

    The visual analog pain scale (VAS) is a straight line in which one end signifies absence of pain and the other means the worst pain imaginable. The researcher will apply the VAS scale to each patient at each visit to assess pain intensity. At the end of the clinical trial the proportion of patiens with an improvement of pain \>30% will be reported and compared between treatment groups.

    Time frame: 3 months

  3. Assess the proportion of patients who reported >50% improvement in pain intensity measured through VAS at 12 weeks per treatment group

    The visual analog pain scale (VAS) is a straight line in which one end signifies absence of pain and the other means the worst pain imaginable. The researcher will apply the VAS scale to each patient at each visit to assess pain intensity. At the end of the clinical trial the proportion of patiens with an improvement of pain \>50% will be reported and compared between treatment groups.

    Time frame: 3 months

  4. Assess at what time of follow-up the greatest reduction in pain intensity was achieved, measured through VAS, per treatment group.

    The visual analog pain scale (VAS) is a straight line in which one end signifies absence of pain and the other means the worst pain imaginable. The researcher will apply the VAS scale to each patient at each visit to assess time of greatest reduction in pain intensity.

    Time frame: 3 months

  5. Assess and compare the degree of physical disability due to low back pain, measured through the Oswestry disability questionnaire at 4 and 12 weeks per treatment group.

    The Oswestry questionnaire has been designed to give us information as to how the back pain has affected the ability to manage everyday life of patients, it classifies QOL as: no disability, mild disability, moderate disability, severe disability and completely disabled. The disability degree would be compared.

    Time frame: 3 months

  6. Assess and compare the degree of disability to perform daily activities due to low back pain, reported through Roland-Morris questionnaire at 4 and 12 weeks per group treatment

    The Roland-Morris questionnaire has been designed to assess the activities of daily living functional mobility pain. A maximum score of 24 indicates the greatest degree of disability from pain. The disability degree would be compared.

    Time frame: 3 months

  7. Assess and compare health status through the 5-level, 5-dimensions EuroQol questionnaire (EQ-5D-5L) at 12 weeks from baseline in each group of treatment

    The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS)The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can image' and 'The worst health you can image'.

    Time frame: 3 months

  8. Report the number of patients that required dose escalation

    Dose escalation criteria: 1. Increase in VAS values compared to the previous visit. 2. Use of rescue medication at least in three consecutive occasions. 3. Percentage of adherence to treatment ≥ 80% The researcher will assess the need for dose escalation or not in each visit.

    Time frame: 3 months

  9. Report the number of patients who require the use of rescue medication during the clinical trial by treatment group.

    The rescue medication will be tramadol 50 mg: - The patient that considers the need for rescue medication must call the doctor, who will be in charge of applying the VAS scale by telephone. If the doctor considers it necessary, the taking of the rescue medication will be indicated.

    Time frame: 3 months

  10. Report the number of patients who presented therapeutic failure during the study among the treatment groups

    Therapeutic failure will be defined by the principal researcher previous medical consult, the following criteria must be present: * Increase in the parameters of the VAS scale at 12 weeks from baseline * ≥80% to adherence to treatment * The consumption of at least 2 doses of the designated group treatment * The need of use of the rescue medication during 24 consecutive hours * The absence of comorbidities that could increase the pain (knew traumatism during the clinical trial)

    Time frame: 3 months

  11. To report the percentage of therapeutic adherence at 12 weeks of intervention by group of treatment.

    Therapeutic adherence will be defined by the principal researcher. Adherence to treatment will be defined as a consumption ≥ 80% of the doses that the patient should have ingested at the time of the corresponding evaluation.

    Time frame: 3 months

  12. Blood concentration of BUN of the patients included in the study by treatment group

    A blood sample will be taken in each visit reporting BUN parameters. Comparisons of serum levels between groups will be made.

    Time frame: 3 months

  13. Blood concentration of glucose of the patients included in the study by treatment group

    A blood sample will be taken in each visit reporting glucose parameters. Comparisons of serum levels between groups will be made.

    Time frame: 3 months

  14. Blood concentration of urea of the patients included in the study by treatment group

    A blood sample will be taken in each visit reporting urea parameters. Comparisons of serum levels between groups will be made.

    Time frame: 3 months

  15. Blood concentration of creatinin of the patients included in the study by treatment group

    A blood sample will be taken in each visit reporting creatinin parameters. Comparisons of serum levels between groups will be made.

    Time frame: 3 months

  16. Blood concentration of Alkaline Phosphatase of the patients included in the study by treatment group

    A blood sample will be taken in each visit reporting Alkaline Phosphatase parameters. Comparisons of serum levels between groups will be made.

    Time frame: 3 months

  17. Blood concentration of total bilirrubin of the patients included in the study by treatment group

    A blood sample will be taken in each visit reporting total bilirrubin parameters. Comparisons of serum levels between groups will be made.

    Time frame: 3 months

07

Study locations

1 site
  • Laboratorio Silanes, S.A. de C.V.
    Mexico City, 11000, Mexico
08

References and documents

Publications

  • Ponce-Monter HA, Ortiz MI, Garza-Hernandez AF, Monroy-Maya R, Soto-Rios M, Carrillo-Alarcon L, Reyes-Garcia G, Fernandez-Martinez E. Effect of diclofenac with B vitamins on the treatment of acute pain originated by lower-limb fracture and surgery. Pain Res Treat. 2012;2012:104782. doi: 10.1155/2012/104782. Epub 2011 Oct 31. PubMed 22135737 ↗
  • Antonucci R, Zaffanello M, Puxeddu E, Porcella A, Cuzzolin L, Pilloni MD, Fanos V. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012 May 1;13(4):474-90. doi: 10.2174/138920012800166607. PubMed 22299823 ↗
  • Raffaeli W, Arnaudo E. Pain as a disease: an overview. J Pain Res. 2017 Aug 21;10:2003-2008. doi: 10.2147/JPR.S138864. eCollection 2017. PubMed 28860855 ↗
  • Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, Woolf A, Vos T, Buchbinder R. A systematic review of the global prevalence of low back pain. Arthritis Rheum. 2012 Jun;64(6):2028-37. doi: 10.1002/art.34347. Epub 2012 Jan 9. PubMed 22231424 ↗
  • Kongsted A, Kent P, Axen I, Downie AS, Dunn KM. What have we learned from ten years of trajectory research in low back pain? BMC Musculoskelet Disord. 2016 May 21;17:220. doi: 10.1186/s12891-016-1071-2. PubMed 27209166 ↗
  • Morlion B. Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. Curr Med Res Opin. 2011 Jan;27(1):11-33. doi: 10.1185/03007995.2010.534446. Epub 2010 Nov 18. PubMed 21083513 ↗
  • Knezevic NN, Candido KD, Vlaeyen JWS, Van Zundert J, Cohen SP. Low back pain. Lancet. 2021 Jul 3;398(10294):78-92. doi: 10.1016/S0140-6736(21)00733-9. Epub 2021 Jun 8. PubMed 34115979 ↗
  • Ho KY, Gwee KA, Cheng YK, Yoon KH, Hee HT, Omar AR. Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice. J Pain Res. 2018 Sep 20;11:1937-1948. doi: 10.2147/JPR.S168188. eCollection 2018. PubMed 30288088 ↗
  • Ajmone-Cat MA, Bernardo A, Greco A, Minghetti L. Non-Steroidal Anti-Inflammatory Drugs and Brain Inflammation: Effects on Microglial Functions. Pharmaceuticals (Basel). 2010 Jun 14;3(6):1949-1965. doi: 10.3390/ph3061949. PubMed 27713336 ↗
  • Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PubMed 29126136 ↗
  • Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb. No abstract available. PubMed 22336956 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jan 2025, 8 months.

Of 35 phase 3 interventional studies under Low Back Pain, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2024
First posted
Jul 23, 2024
StartActual
Apr 11, 2024
Primary completionActual
Jan 1, 2025
CompletionActual
Jan 7, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06516094
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
Apr 11, 2024
Primary completion
Jan 1, 2025
Completion
Jan 7, 2025
Last update
Apr 4, 2025

Study contacts

Juan L Torres-Méndez
principal investigator · Clínica de Ozonoterapia RGH, A.C.
Raul Coca-Nuñez
principal investigator · CICMEX
Adelfia Urenda-Quezada
principal investigator · Imacen S.A. de C.V.
Ma. Dolores Alonso-Martinez
principal investigator · Servicios Avanzados de Investigación Medica Mediadvance S.C.
Ramon F Villalobos-Bojorquez
principal investigator · Clinical Research Institute, S.C.
Rodrigo Suárez-Otero
principal investigator · Consultorio Médico "Dr. Rodrigo Suárez Otero"

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion